Status:
COMPLETED
A Study of Evacetrapib and Rifampin in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of ...
Eligibility Criteria
Inclusion
- Overtly healthy males and females (of non child-bearing potential)
- Have a body mass index of 18 to 32 kilograms per square meter (kg/m\^2), inclusive, at screening
Exclusion
- Have known allergies to evacetrapib, rifampin, related compounds or any components of either formulation, or history of significant allergic disease as determined by the investigator
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT01908582
Start Date
July 1 2013
End Date
September 1 2013
Last Update
October 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Madison, Wisconsin, United States, 53704